D.E. Shaw & Co
BEAM icon

D.E. Shaw & Co’s Beam Therapeutics BEAM Stock Holding History

D.E. Shaw & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$1.6M – 4749
2021
Q1 		$1.6M Buy
+20,000
New +$1.9M ﹤0.01% 2773

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

D.E. Shaw & Co's BEAM Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 27,935 shares — an estimated $774K sold.

D.E. Shaw & Co first reported a position in BEAM in Q1 2021 and held it in 6 quarters. The position peaked at $5.16M in Q3 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,935 Beam Therapeutics shares in Q1 2026, an estimated $774K.
  • D.E. Shaw & Co first reported a position in Beam Therapeutics in Q1 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's Beam Therapeutics position peaked at $5.16M in Q3 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.